Skip to main content
Premium Trial:

Request an Annual Quote

Applied DNA Prices $12M Public Stock, Warrant Offering

NEW YORK — Applied DNA Sciences on Thursday priced a planned $12 million public offering of stock and warrants.

Through the offering, the Stony Brook, New York-based company will offer 3 million shares of its common stock, along with Series A and B warrants to purchase up to 6 million shares of common stock, at $4 per share and associated warrants. Both classes of warrants will be immediately exercisable at $4 apiece.

The offering is expected to close on or around Aug. 8.

Applied DNA, which earlier this year closed a roughly $4.2 million registered direct stock offering, said it will use the proceeds of the public offering to further the development of its therapeutic DNA production and molecular diagnostic testing services, as well as for general corporate purposes.

The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.